Current issues in adjuvant treatment of stage II colon cancer

Thierry André, Daniel Sargent, Josep Tabernero, Michael O'Connell, Marc Buyse, Alberto Sobrero, Jean Louis Misset, Corrado Boni, Aimery De Gramont

Research output: Contribution to journalReview articlepeer-review

77 Scopus citations


Background: Adjuvant chemotherapy with 5-fluorouracil modulated by folinic acid, combined with oxaliplatin, has now become an accepted standard of care for patients with stage III colon cancer. In contrast, the use of adjuvant therapy for stage II patients remains controversial, and the identification of reliable prognostic factors to aid therapeutic decision making is crucial. Methods: The authors critically review the results of clinical trials and meta-analyses investigating the value of adjuvant chemotherapy for stage II patients, emphasizing the heterogeneous nature of this population and the difficulty of performing clinical trials with sufficient power to reliably assess treatment efficacy. They also discuss the evidence concerning potential prognostic factors, particularly molecular markers. Results: Available clinical trial data do not support the routine use of adjuvant chemotherapy for all stage II patients but suggest that it should be considered, particularly for certain high-risk patients. Recent guidelines advocate considering factors such as tumor differentiation, tumor perforation, number of lymph nodes examined, and T stage when assessing the likely benefit:risk ratio. Microsatellite instability and allelic imbalance seem to be strong predictors of good and poor prognosis, respectively, and in the near future, therapeutic decision-making models are likely to be further refined by the inclusion of such molecular markers. Conclusions: There is growing evidence that the prognosis of certain stage II patients with unfavorable prognostic factors can be improved by adjuvant chemotherapy, and increasingly refined tools are now available to define those most likely to benefit. Referral of stage II patients for individual assessment is strongly recommended.

Original languageEnglish (US)
Pages (from-to)887-898
Number of pages12
JournalAnnals of surgical oncology
Issue number6
StatePublished - Jun 2006


  • 5-Fluorouracil
  • Adjuvant chemotherapy
  • Colon cancer, stage II
  • Leucovorin
  • Oxaliplatin

ASJC Scopus subject areas

  • Surgery
  • Oncology


Dive into the research topics of 'Current issues in adjuvant treatment of stage II colon cancer'. Together they form a unique fingerprint.

Cite this